Quick Pitch
NephTech prides itself as a provider of a user-centric, non-invasive blood vessel surveillance for dialysis centres and kidney failure patients to improve on the current deficit for early detection of stenotic events.
Product/Service Details
An integrated system of sensory hardware, proprietary predictive signal algorithm and cloud computing technologies, NephTech’s first-of-its-kind non-invasive measurement solution seeks to allow patients, care-givers and dialysis centres to identify early stage renal disease complications within seconds.
Problem/Opportunity
End Stage Renal Disease (“ESRD”) is the final stage of chronic kidney disease, culminating in a loss of kidney functions. A typical treatment plan will involve an organ transplant (an 8-year waiting list in Singapore) or ongoing dialysis treatment programme – 3 treatment sessions per week (4 hours per treatment session) for the rest of their lives.
Treating ESRD with dialysis treatment is complex and financially draining. Vascular surgeons have to create a ‘special’ blood vessel in patients, allow the blood vessel to mature over a 3-month period before dialysis nurses can use this matured blood vessel for dialysis treatments. Through the frequent needling of this blood vessel during dialysis treatments, the blood vessel becomes prone to complications, including blood vessel narrowing (stenosis) leading up to formation of blood clot (thrombosis). Current commonly used technique to monitor requires at least 15 minutes of preparation, calibration and measurement, making it very inefficient. There are clinical evidence demonstrating cost saving benefits with early detection of these complications.
Solution
NephTech, a Singapore-based medical technology company, has been quietly revolutionising this process.
Using an integrated system of sensory hardware, proprietary predictive signal algorithm and cloud computing technologies, NephTech’s first-of-its-kind non-invasive, needle-less measurement solution seeks to allow patients, care-givers and dialysis centres to identify early stage renal disease complications within seconds. The principle behind this predictive technology has also been demonstrated scientifically to be accurate.
Traction & Accomplishments
The company has undergone independent assessments of NephTech business viability, market potential and technical capability, made by experienced panellists from the MedTech industry.
How We're Different
Commercial Opportunities:
Revenue model:
Team
Co-founders: Dr. James Lim & Ms. Toh Yanling
Ms. Edwina Alias (Acoustic Signal Processing), Mr Wang Shengxiao (Quality Management System) & Mr. Srimanta Mohanty (Backend Architecture)
Advisors/ Investors/ Stakeholders:
Contact